The tumor microenvironment creates physical, metabolic, and immune barriers that limit cancer therapy.
Iron-based materials offer magnetic, catalytic, and immune-regulating functions to address these barriers.
Sequential microenvironment reprogramming (SMR) links three stages, from transport to immune remodeling.
Rather than following a fixed sequence, SMR guides interventions based on biological responses.
Its clinical potential requires reliable biomarkers, patient stratification, and rigorous validation.
| [1] | Mitchell M.J., Billingsley M.M., Haley R.M., et al. (2021). Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20:101−124. DOI:10.1038/s41573-020-0090-8 |
| [2] | Shi J., Kantoff P.W., Wooster R., et al. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 17:20−37. DOI:10.1038/nrc.2016.108 |
| [3] | Matsumura Y. and Maeda H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:6387-6392. https://aacrjournals.org/cancerres/article/46/12_Part_1/6387/490212/A-New-Concept-for-Macromolecular-Therapeutics-in |
| [4] | Youn Y.S. and Bae Y.H. (2018). Perspectives on the past, present, and future of cancer nanomedicine. Adv. Drug Deliv. Rev. 130:3−11. DOI:10.1016/j.addr.2018.05.008 |
| [5] | Wilhelm S., Tavares A.J., Dai Q., et al. (2016). Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1:16014. DOI:10.1038/natrevmats.2016.14 |
| [6] | Fukumura D., Kloepper J., Amoozgar Z., et al. (2018). Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat. Rev. Clin. Oncol. 15:325−340. DOI:10.1038/nrclinonc.2018.29 |
| [7] | De Palma M., Biziato D. and Petrova T.V. (2017). Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17:457−474. DOI:10.1038/nrc.2017.51 |
| [8] | Jain R.K. (2014). Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26:605−622. DOI:10.1016/j.ccell.2014.10.006 |
| [9] | Sahai E., Astsaturov I., Cukierman E., et al. (2020). A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20:174−186. DOI:10.1038/s41568-019-0238-1 |
| [10] | Stylianopoulos T., Martin J.D., Chauhan V.P., et al. (2012). Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc. Natl. Acad. Sci. USA 109:15101−15108. DOI:10.1073/pnas.1213353109 |
| [11] | Nia H.T., Munn L.L. and Jain R.K. (2020). Physical traits of cancer. Science 370. DOI:10.1126/science.aaz0868. |
| [12] | Semenza G.L. (2012). Hypoxia-inducible factors in physiology and medicine. Cell 148:399−408. DOI:10.1016/j.cell.2012.01.021 |
| [13] | Petrova V., Annicchiarico-Petruzzelli M., Melino G., et al. (2018). The hypoxic tumour microenvironment. Oncogenesis 7:10. DOI:10.1038/s41389-017-0011-9 |
| [14] | Pavlova Natalya N. and Thompson Craig B. (2016). The emerging hallmarks of cancer metabolism. Cell Metab. 23:27−47. DOI:10.1016/j.cmet.2015.12.006 |
| [15] | Zhang W., Wang P., Yuan G., et al. (2026). Fatty acid metabolic reprogramming in the tumor microenvironment: Unraveling mechanisms and therapeutic prospects. Genes Dis. 13:101772. DOI:10.1016/j.gendis.2025.101772 |
| [16] | Joyce J.A. and Fearon D.T. (2015). T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74−80. DOI:10.1126/science.aaa6204 |
| [17] | Hinshaw D.C. and Shevde L.A. (2019). The tumor microenvironment innately modulates cancer progression. Cancer Res. 79:4557−4566. DOI:10.1158/0008-5472.Can-18-3962 |
| [18] | Binnewies M., Roberts E.W., Kersten K., et al. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24:541−550. DOI:10.1038/s41591-018-0014-x |
| [19] | Anderson N.M. and Simon M.C. (2020). The tumor microenvironment. Curr. Biol. 30:R921−R925. DOI:10.1016/j.cub.2020.06.081 |
| [20] | Valkenburg K.C., de Groot A.E. and Pienta K.J. (2018). Targeting the tumour stroma to improve cancer therapy. Nat. Rev. Clin. Oncol. 15:366−381. DOI:10.1038/s41571-018-0007-1 |
| [21] | Martin J.D., Cabral H., Stylianopoulos T., et al. (2020). Improving cancer immunotherapy using nanomedicines: Progress, opportunities and challenges. Nat. Rev. Clin. Oncol. 17:251−266. DOI:10.1038/s41571-019-0308-z |
| [22] | Liu Y., Sun D., Li W., et al. (2026). Nanomedicine-mediated modulation of tumor metabolism for enhanced immunotherapy. J. Control. Release 390:114587. DOI:10.1016/j.jconrel.2025.114587 |
| [23] | Jain R.K. (2005). Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58−62. DOI:10.1126/science.1104819 |
| [24] | Galluzzi L., Buqué A., Kepp O., et al. (2017). Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17:97−111. DOI:10.1038/nri.2016.107 |
| [25] | Sengupta S., Eavarone D., Capila I., et al. (2005). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436:568−572. DOI:10.1038/nature03794 |
| [26] | Mpekris F., Panagi M., Voutouri C., et al. (2021). Normalizing the microenvironment overcomes vessel compression and resistance to nano-immunotherapy in breast cancer lung metastasis. Adv. Sci. (Weinh) 8:2001917. DOI:10.1002/advs.202001917 |
| [27] | Mpekris F., Voutouri C., Baish J.W., et al. (2020). Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc. Natl. Acad. Sci. USA 117:3728−3737. DOI:10.1073/pnas.1919764117 |
| [28] | Yu Y., Song Z., Zhu A., et al. (2026). Sequential tumor microenvironment reprogramming by nanoplatform potentiates sonodynamic-chemodynamic therapy and immune checkpoint blockade in breast cancer. Adv. Sci. (Weinh) 13:e12135. DOI:10.1002/advs.202512135 |
| [29] | Yu E. Y., Bishop M., Zheng B., et al. (2017). Magnetic particle imaging: A novel in vivo imaging platform for cancer detection. Nano Lett. 17:1648−1654. DOI:10.1021/acs.nanolett.6b04865 |
| [30] | Bulte J.W. and Kraitchman D.L. (2004). Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 17:484−499. DOI:10.1002/nbm.924 |
| [31] | Yang W. S., SriRamaratnam R., Welsch M.E., et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317−331. DOI:10.1016/j.cell.2013.12.010 |
| [32] | Huo M., Wang L., Chen Y., et al. (2017). Tumor-selective catalytic nanomedicine by nanocatalyst delivery. Nat. Commun. 8:357. DOI:10.1038/s41467-017-00424-8 |
| [33] | Tang Z., Liu Y., He M., et al. (2019). Chemodynamic therapy: Tumour microenvironment-mediated fenton and fenton-like reactions. Angew. Chem. Int. Ed. 58:946−956. DOI:10.1002/anie.201805664 |
| [34] | Dixon S.J., Lemberg K.M., Lamprecht M.R., et al. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149:1060−1072. DOI:10.1016/j.cell.2012.03.042 |
| [35] | Jiang X., Stockwell B.R. and Conrad M. (2021). Ferroptosis: Mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22:266−282. DOI:10.1038/s41580-020-00324-8 |
| [36] | Wan X., Song L., Pan W., et al. (2020). Tumor-targeted cascade nanoreactor based on metal-organic frameworks for synergistic ferroptosis-starvation anticancer therapy. ACS Nano 14:11017−11028. DOI:10.1021/acsnano.9b07789 |
| [37] | Xue C.C., Li M.H., Zhao Y., et al. (2020). Tumor microenvironment-activatable Fe-doxorubicin preloaded amorphous CaCO(3) nanoformulation triggers ferroptosis in target tumor cells. Sci. Adv. 6:eaax1346. DOI:10.1126/sciadv.aax1346 |
| [38] | Chen X. and Song E. (2019). Turning foes to friends: Targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18:99−115. DOI:10.1038/s41573-018-0004-1 |
| [39] | Diop-Frimpong B., Chauhan V.P., Krane S., et al. (2011). Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. USA 108:2909−2914. DOI:10.1073/pnas.1018892108 |
| [40] | Shapiro B., Kulkarni S., Nacev A., et al. (2015). Open challenges in magnetic drug targeting. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7:446−457. DOI:10.1002/wnan.1311 |
| [41] | Liu J.F., Lan Z., Ferrari C., et al. (2020). Use of oppositely polarized external magnets to improve the accumulation and penetration of magnetic nanocarriers into solid tumors. ACS Nano 14:142−152. DOI:10.1021/acsnano.9b05660 |
| [42] | Kim D.H., Rozhkova E.A., Ulasov I.V., et al. (2010). Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat. Mater. 9:165−171. DOI:10.1038/nmat2591 |
| [43] | Cheng Y., Muroski M.E., Petit D.C.M.C., et al. (2016). Rotating magnetic field induced oscillation of magnetic particles for in vivo mechanical destruction of malignant glioma. J. Control. Release 223:75−84. DOI:10.1016/j.jconrel.2015.12.028 |
| [44] | Shen Y., Wu C., Uyeda T.Q.P., et al. (2017). Elongated nanoparticle aggregates in cancer cells for mechanical destruction with low frequency rotating magnetic field. Theranostics 7:1735−1748. DOI:10.7150/thno.18352 |
| [45] | Chauhan V.P., Boucher Y., Ferrone C.R., et al. (2014). Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 26:14−15. DOI:10.1016/j.ccr.2014.06.003 |
| [46] | Gu Z., Liu T., Liu C., et al. (2021). Ferroptosis-strengthened metabolic and inflammatory regulation of tumor-associated macrophages provokes potent tumoricidal activities. Nano Lett. 21:6471−6479. DOI:10.1021/acs.nanolett.1c01401 |
| [47] | Zanganeh S., Hutter G., Spitler R., et al. (2016). Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11:986−994. DOI:10.1038/nnano.2016.168 |
| [48] | Recalcati S., Locati M., Marini A., et al. (2010). Differential regulation of iron homeostasis during human macrophage polarized activation. Eur. J. Immunol. 40:824−835. DOI:10.1002/eji.200939889 |
| [49] | Costa da Silva M., Breckwoldt M.O., Vinchi F., et al. (2017). Iron induces anti-tumor activity in tumor-associated macrophages. Front. Immunol. 8:1479. DOI:10.3389/fimmu.2017.01479 |
| [50] | Gu Z., Liu T., Tang J., et al. (2019). Mechanism of iron oxide-induced macrophage activation: The impact of composition and the underlying signaling pathway. J. Am. Chem. Soc. 141:6122−6126. DOI:10.1021/jacs.8b10904 |
| [51] | Jansen C.S., Prokhnevska N., Master V.A., et al. (2019). An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576:465−470. DOI:10.1038/s41586-019-1836-5 |
| [52] | Sautès-Fridman C., Petitprez F., Calderaro J., et al. (2019). Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19:307−325. DOI:10.1038/s41568-019-0144-6 |
| [53] | Schumacher T.N. and Thommen D.S. (2022). Tertiary lymphoid structures in cancer. Science 375:eabf9419. DOI:10.1126/science.abf9419 |
| [54] | Helmink B.A., Reddy S.M., Gao J., et al. (2020). B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577:549−555. DOI:10.1038/s41586-019-1922-8 |
| [55] | Cabrita R., Lauss M., Sanna A., et al. (2020). Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577:561−565. DOI:10.1038/s41586-019-1914-8 |
| [56] | Petitprez F., de Reyniès A., Keung E.Z., et al. (2020). B cells are associated with survival and immunotherapy response in sarcoma. Nature 577:556−560. DOI:10.1038/s41586-019-1906-8 |
| [57] | Stylianopoulos T., Martin J.D., Snuderl M., et al. (2013). Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res. 73:3833−3841. DOI:10.1158/0008-5472.Can-12-4521 |
| [58] | Brand A., Singer K., Koehl G.E., et al. (2016). LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24:657−671. DOI:10.1016/j.cmet.2016.08.011 |
| [59] | Recalcati S., Locati M., Gammella E., et al. (2012). Iron levels in polarized macrophages: Regulation of immunity and autoimmunity. Autoimmun. Rev. 11:883−889. DOI:10.1016/j.autrev.2012.03.003 |
| [60] | Manz D.H., Blanchette N.L., Paul B.T., et al. (2016). Iron and cancer: Recent insights. Ann. N. Y. Acad. Sci. 1368:149−161. DOI:10.1111/nyas.13008 |
| [61] | Yang Y., Liu Y., Song L., et al. (2023). Iron oxide nanoparticle-based nanocomposites in biomedical application. Trends Biotechnol. 41:1471−1487. DOI:10.1016/j.tibtech.2023.06.001 |
| [62] | Chen G., Roy I., Yang C., et al. (2016). Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem. Rev. 116:2826−2885. DOI:10.1021/acs.chemrev.5b00148 |
| [63] | Lim E.K., Kim T., Paik S., et al. (2015). Nanomaterials for theranostics: Recent advances and future challenges. Chem. Rev. 115:327−394. DOI:10.1021/cr300213b |
| [64] | Gleich B. and Weizenecker J. (2005). Tomographic imaging using the nonlinear response of magnetic particles. Nature 435:1214−1217. DOI:10.1038/nature03808 |
| [65] | Makela A.V., Gaudet J.M., Schott M.A., et al. (2020). Magnetic particle imaging of macrophages associated with cancer: Filling the voids left by iron-based magnetic resonance imaging. Mol. Imaging Biol. 22:958−968. DOI:10.1007/s11307-020-01473-0 |
| [66] | Park S.J., Han S.R., Kang Y.H., et al. (2022). In vivo preclinical tumor-specific imaging of superparamagnetic iron oxide nanoparticles using magnetic particle imaging for cancer diagnosis. Int. J. Nanomedicine 17:3711−3722. DOI:10.2147/ijn.S372494 |
| [67] | Dadfar S.M., Camozzi D., Darguzyte M., et al. (2020). Size-isolation of superparamagnetic iron oxide nanoparticles improves MRI, MPI and hyperthermia performance. J. Nanobiotechnology 18:22. DOI:10.1186/s12951-020-0580-1 |
| [68] | Kumar P.P.P., Nafiujjaman M., Makela A.V., et al. (2025). Development of iron oxide nanochains as a sensitive magnetic particle imaging tracer for cancer detection. ACS Appl. Mater. Interfaces 17:20859−20871. DOI:10.1021/acsami.5c00332 |
| [69] | Ejima H., Richardson J.J., Liang K., et al. (2013). One-step assembly of coordination complexes for versatile film and particle engineering. Science 341:154−157. DOI:10.1126/science.1237265 |
| [70] | Zhang C., Bu W., Ni D., et al. (2016). Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized Fenton reaction. Angew. Chem. Int. Ed. 55:2101−2106. DOI:10.1002/anie.201510031 |
| [71] | Yang G., Xu L., Chao Y., et al. (2017). Hollow MnO(2) as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat. Commun. 8:902. DOI:10.1038/s41467-017-01050-0 |
| [72] | Wang C., Guan Y., Lv M., et al. (2018). Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses. Immunity 48:675−687.e677. DOI:10.1016/j.immuni.2018.03.017 |
| [73] | Lin L.-S., Huang T., Song J., et al. (2019). Synthesis of copper peroxide nanodots for H2O2 self-supplying chemodynamic therapy. J. Am. Chem. Soc. 141:9937−9945. DOI:10.1021/jacs.9b03457 |
| [74] | Tsvetkov P., Coy S., Petrova B., et al. (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 375:1254−1261. DOI:10.1126/science.abf0529 |
| [75] | Nam J., Son S., Ochyl L.J., et al. (2018). Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat. Commun. 9:1074. DOI:10.1038/s41467-018-03473-9 |
| [76] | Zheng P., Ding B., Shi R., et al. (2021). A Multichannel Ca(2+) Nanomodulator for multilevel mitochondrial destruction-mediated cancer therapy. Adv. Mater. 33:e2007426. DOI:10.1002/adma.202007426 |
| [77] | Rhim A.D., Oberstein P.E., Thomas D.H., et al. (2014). Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735−747. DOI:10.1016/j.ccr.2014.04.021 |
| [78] | Provenzano P.P., Cuevas C., Chang A.E., et al. (2012). Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21:418−429. DOI:10.1016/j.ccr.2012.01.007 |
| [79] | Özdemir B.C., Pentcheva-Hoang T., Carstens J.L., et al. (2014). Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:719-734. DOI:10.1016/j.ccr.2014.04.005 |
| [80] | Zhang Z., Chen X., Zhang B., et al. (2026). Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets. Biochim. Biophys. Acta Rev. Cancer 1881:189517. DOI:10.1016/j.bbcan.2025.189517 |
| [81] | Heldin C.H., Rubin K., Pietras K., et al. (2004). High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4:806−813. DOI:10.1038/nrc1456 |
| [82] | Chauhan V.P., Martin J.D., Liu H., et al. (2013). Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4:2516. DOI:10.1038/ncomms3516 |
| [83] | Tian L., Goldstein A., Wang H., et al. (2017). Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544:250−254. DOI:10.1038/nature21724 |
| [84] | O'Connor J.P., Aboagye E.O., Adams J.E., et al. (2017). Imaging biomarker roadmap for cancer studies. Nat. Rev. Clin. Oncol. 14:169−186. DOI:10.1038/nrclinonc.2016.162 |
| [85] | Winkler J., Abisoye-Ogunniyan A., Metcalf K.J., et al. (2020). Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11:5120. DOI:10.1038/s41467-020-18794-x |
| [86] | Levental K.R., Yu H., Kass L., et al. (2009). Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139:891−906. DOI:10.1016/j.cell.2009.10.027 |
| [87] | Kalluri R. (2016). The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16:582−598. DOI:10.1038/nrc.2016.73 |
| [88] | Huang Z., Chen J., Zhu T., et al. (2025). Cancer-associated fibroblasts in the tumor microenvironment: Heterogeneity, crosstalk mechanisms, and therapeutic implications. Mol. Cancer 25:19. DOI:10.1186/s12943-025-02533-1 |
| [89] | Hakim N., Patel R., Devoe C., et al. (2019). Why HALO 301 failed and implications for treatment of pancreatic cancer. Pancreas (Fairfax) 3:e1−e4. DOI:10.17140/POJ-3-e010 |
| [90] | Cai W., Chen Y., Dai S., et al. (2025). Hyaluronic acid and its role in pancreatic cancer: Mechanisms of tumor progression, drug resistance, and therapeutic targeting. Pharmacol Res. 221:107958. DOI:10.1016/j.phrs.2025.107958 |
| [91] | Li L., Wen J., Xu H., et al. (2026). ECM-responsive nanomedicine to enhance immunotherapy in pancreatic cancer. Colloids Surf. B Biointerfaces 260:115356. DOI:10.1016/j.colsurfb.2025.115356 |
| [92] | Song G., Chen Y., Liang C., et al. (2016). Catalase-loaded TaOx nanoshells as bio-nanoreactors combining high-Z element and enzyme delivery for enhancing radiotherapy. Adv. Mater. 28:7143−7148. DOI:10.1002/adma.201602111 |
| [93] | Chen Q., Feng L., Liu J., et al. (2016). Intelligent albumin-MnO2 nanoparticles as pH-/H2O2 -responsive dissociable nanocarriers to modulate tumor hypoxia for effective combination therapy. Adv. Mater. 28:7129−7136. DOI:10.1002/adma.201601902 |
| [94] | Cheng Y., Cheng H., Jiang C., et al. (2015). Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. Nat. Commun. 6:8785. DOI:10.1038/ncomms9785 |
| [95] | Gao S., Lin H., Zhang H., et al. (2019). Nanocatalytic tumor therapy by biomimetic dual inorganic nanozyme-catalyzed cascade reaction. Adv. Sci. (Weinh) 6:1801733. DOI:10.1002/advs.201801733 |
| [96] | Chen H., Tian J., He W., et al. (2015). H2O2-activatable and O2-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells. J. Am. Chem. Soc. 137:1539−1547. DOI:10.1021/ja511420n |
| [97] | Yang L., Zhang W.H., Li Y., et al. (2025). Oxygen nanobubbles enhance ICG/Fe(III)-mediated dual-modal therapy to induce ferroptosis in tumor treatment. ACS Appl. Mater. Interfaces 17:11718−11730. DOI:10.1021/acsami.4c19604 |
| [98] | Prasad S.B., Shinde A., Srinivasrao D.A., et al. (2025). Metal-organic frameworks as therapeutic chameleons: Revolutionizing the cancer therapy employing novel nanoarchitectonics. Asian J. Pharm. Sci. 20:101054. DOI:10.1016/j.ajps.2025.101054 |
| [99] | Jiao L., Yan H., Wu Y., et al. (2020). When nanozymes meet single-atom catalysis. Angew. Chem. Int. Ed. 59:2565−2576. DOI:10.1002/anie.201905645 |
| [100] | Huang L., Chen J., Gan L., et al. (2019). Single-atom nanozymes. Sci. Adv. 5:eaav5490. DOI:10.1126/sciadv.aav5490 |
| [101] | Horcajada P., Chalati T., Serre C., et al. (2010). Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat. Mater. 9:172−178. DOI:10.1038/nmat2608 |
| [102] | Ghaemi B. and Javad Hajipour M. (2023). Tumor acidic environment directs nanoparticle impacts on cancer cells. J. Colloid Interface Sci. 634:684−692. DOI:10.1016/j.jcis.2022.12.019 |
| [103] | Liu Y., Cai X., Liu J., et al. (2025). The role of redox homeostasis in tumor progression: Implications for cancer therapy. Acta Biomater. 204:156−186. DOI:10.1016/j.actbio.2025.07.067 |
| [104] | Doll S., Proneth B., Tyurina Y.Y., et al. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13:91−98. DOI:10.1038/nchembio.2239 |
| [105] | Kagan V.E., Mao G., Qu F., et al. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13:81−90. DOI:10.1038/nchembio.2238 |
| [106] | Hu Y., Li Z., Li M., et al. (2025). Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. Mol. Cell 85:4602−4620.e4609. DOI:10.1016/j.molcel.2025.11.023 |
| [107] | Meng X., Deng J., Liu F., et al. (2019). Triggered all-active metal organic framework: Ferroptosis machinery contributes to the apoptotic photodynamic antitumor therapy. Nano Lett. 19:7866−7876. DOI:10.1021/acs.nanolett.9b02904 |
| [108] | Zhao Y., Yang S., Huang L., et al. (2025). MUC1 drives ferroptosis resistance in ICC via Src-mediated FSP1 deubiquitination and myristoylation. Clin. Transl. Med. 15:e70495. DOI:10.1002/ctm2.70495 |
| [109] | Hai Y., Lin R., Liao W., et al. (2025). Dihydroorotate dehydrogenase inhibition activates STING pathway and pyroptosis to enhance NK cell-dependent tumor immunotherapy. Mol. Biomed. 6:87. DOI:10.1186/s43556-025-00339-7 |
| [110] | Ma C., Han L., Yao H., et al. (2026). Modulating G6PD/PGD to overcome FSP1/DHODH-mediated ferroptosis defence: A novel oridonin derivative suppresses liver cancer. Br. J. Pharmacol. 183:249−267. DOI:10.1111/bph.70160 |
| [111] | Li W., Panacek D., Xie Q., et al. (2025). Precision fishing for enzyme-like materials: Identifying and engineering mesoporous catalytic sites for ferroptosis induction. Nano Lett. 25:11356−11364. DOI:10.1021/acs.nanolett.5c02476 |
| [112] | Stockwell B.R., Friedmann Angeli J.P., Bayir H., et al. (2017). Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171:273−285. DOI:10.1016/j.cell.2017.09.021 |
| [113] | Stockwell B.R. (2022). Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell 185:2401−2421. DOI:10.1016/j.cell.2022.06.003 |
| [114] | Dixon S.J. and Stockwell B.R. (2019). The hallmarks of ferroptosis. Annu. Rev. Cancer Biol. 3:35−54. DOI:10.1146/annurev-cancerbio-030518-055844 |
| [115] | Lei G., Zhuang L. and Gan B. (2022). Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22:381−396. DOI:10.1038/s41568-022-00459-0 |
| [116] | Hangauer M.J., Viswanathan V.S., Ryan M.J., et al. (2017). Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551:247−250. DOI:10.1038/nature24297 |
| [117] | Shen Z., Liu T., Li Y., et al. (2018). Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano 12:11355−11365. DOI:10.1021/acsnano.8b06201 |
| [118] | Su L., Yang S., Yuan H., et al. (2026). Cell membrane biomimetic drug delivery systems based on ferroptosis mechanism for anticancer treatment. Adv. Healthc. Mater. 15:e04993. DOI:10.1002/adhm.202504993 |
| [119] | Gao Y., Xu J., Lai Y., et al. (2025). 2D nanomaterial-triggered ferroptosis in cancer therapy. J. Nanobiotechnology 24:81. DOI:10.1186/s12951-025-03975-x |
| [120] | Ye L.F., Chaudhary K.R., Zandkarimi F., et al. (2020). Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers. ACS Chem. Biol. 15:469−484. DOI:10.1021/acschembio.9b00939 |
| [121] | Lang X., Green M.D., Wang W., et al. (2019). Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 9:1673−1685. DOI:10.1158/2159-8290.Cd-19-0338 |
| [122] | Lei G., Zhang Y., Koppula P., et al. (2020). The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 30:146−162. DOI:10.1038/s41422-019-0263-3 |
| [123] | Zhu T., Shi L., Yu C., et al. (2019). Ferroptosis promotes photodynamic therapy: Supramolecular photosensitizer-inducer nanodrug for enhanced cancer treatment. Theranostics 9:3293−3307. DOI:10.7150/thno.32867 |
| [124] | Bae C., Hernández Millares R., Ryu S., et al. (2024). Synergistic effect of ferroptosis-inducing nanoparticles and X-ray irradiation combination therapy. Small 20:e2310873. DOI:10.1002/smll.202310873 |
| [125] | Duo K., Feng X., Tian X., et al. (2025). Ferroptosis inhibitors: Mechanisms of action and therapeutic potential. Cell. Mol. Life Sci. 82:441. DOI:10.1007/s00018-025-05958-5 |
| [126] | Tang D., Chen X., Kang R., et al. (2021). Ferroptosis: Molecular mechanisms and health implications. Cell Res. 31:107−125. DOI:10.1038/s41422-020-00441-1 |
| [127] | Hirayama T., Niwa M., Hirosawa S., et al. (2020). High-throughput screening for the discovery of iron homeostasis modulators using an extremely sensitive fluorescent probe. ACS Sens. 5:2950−2958. DOI:10.1021/acssensors.0c01445 |
| [128] | Wiernicki B., Maschalidi S., Pinney J., et al. (2022). Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat. Commun. 13:3676. DOI:10.1038/s41467-022-31218-2 |
| [129] | Ma X., Xiao L., Liu L., et al. (2021). CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability. Cell Metab. 33:1001−1012.e1005. DOI:10.1016/j.cmet.2021.02.015 |
| [130] | Xu S., Chaudhary O., Rodríguez-Morales P., et al. (2021). Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors. Immunity 54:1561−1577.e1567. DOI:10.1016/j.immuni.2021.05.003 |
| [131] | Kim R., Hashimoto A., Markosyan N., et al. (2022). Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature 612:338−346. DOI:10.1038/s41586-022-05443-0 |
| [132] | Liu D., Ling Y., Liu W., et al. (2025). Ultrasound-responsive micro/nanobubbles based intelligent theranostic systems for precision tumor therapy. J. Nanobiotechnology 24:83. DOI:10.1186/s12951-025-03959-x |
| [133] | Liu J., Dong R., Yuan B., et al. (2025). Immune cells dying from ferroptosis: Mechanisms and therapeutic opportunities. Cell Death Dis. 16:878. DOI:10.1038/s41419-025-08204-9 |
| [134] | Galluzzi L., Kepp O., Zitvogel L., et al. (2026). Cancer cell death: Cell-autonomous and immunogenic dimensions. Cancer Cell 44:281−305. DOI:10.1016/j.ccell.2025.12.005 |
| [135] | Obeid M., Tesniere A., Ghiringhelli F., et al. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13:54−61. DOI:10.1038/nm1523 |
| [136] | Tang D., Kepp O. and Kroemer G. (2020). Ferroptosis becomes immunogenic: Implications for anticancer treatments. Oncoimmunology 10:1862949. DOI:10.1080/2162402x.2020.1862949 |
| [137] | Krysko D.V., Garg A.D., Kaczmarek A., et al. (2012). Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12:860−875. DOI:10.1038/nrc3380 |
| [138] | Efimova I., Catanzaro E., Van der Meeren L., et al. (2020). Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J. Immunother. Cancer 8. DOI:10.1136/jitc-2020-001369. |
| [139] | Wang W., Green M., Choi J.E., et al. (2019). CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569:270−274. DOI:10.1038/s41586-019-1170-y |
| [140] | Liao P., Wang W., Wang W., et al. (2022). CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 40:365−378.e366. DOI:10.1016/j.ccell.2022.02.003 |
| [141] | Huang Z., Zhou H., Huang S., et al. (2026). Amifostine-iron nanoparacrystalline for tumor-selective immunogenic ferroptosis. Nano Lett. 26:278−287. DOI:10.1021/acs.nanolett.5c05065 |
| [142] | Son S.W., Lee H.J., Kang N., et al. (2025). The E2F1-HMGCR axis promotes ferroptosis resistance in immune refractory tumor cells. Nat. Commun. 16:10849. DOI:10.1038/s41467-025-66282-x |
| [143] | Hu K., Li J., Chen K., et al. (2025). Hypoxia-induced USP13 expression drives ferroptosis resistance and tumor immune evasion in hepatocellular carcinoma through the stabilization of ACLY. Cell Death Discov. 12:28. DOI:10.1038/s41420-025-02869-z |
| [144] | Zhang J., Jin X., Abulaihaiti M., et al. (2025). Hypoxic tumor exosomes suppress macrophage inflammation and ferroptosis via NDUFV2 to enhance bystander tumor radioresistance. Cell Death Dis. 17:109. DOI:10.1038/s41419-025-08357-7 |
| [145] | Li W., Liang L., Liu S., et al. (2025). Inhibin beta A drives colorectal cancer progression through macrophage M2 polarization and mitochondria-dependent ferroptosis suppression. Signal Transduct. Target. Ther. 10:420. DOI:10.1038/s41392-025-02518-y |
| [146] | He Q. and Zhang L. (2025). Nanozyme-driven remodeling of the immune microenvironment: From catalytic therapy to precise immune regulation. Nanoscale 17:25947−25963. DOI:10.1039/d5nr03420e |
| [147] | Ren Y., Cui Y., Wang Z., et al. (2025). ALDH3A2 negatively orchestrates gastric cancer progression through a synergistic induction of ferroptosis and ferroptosis-driven macrophage reprogramming. Cell Death Dis. 17:97. DOI:10.1038/s41419-025-08364-8 |
| [148] | Hefetz R., Lianski S., Ghantous L., et al. (2025). Macrophages rescue cells from ferroptotic death. Cell Death Dis. 17:66. DOI:10.1038/s41419-025-08277-6 |
| [149] | Wang Z., Xu W., Zhao L., et al. (2026). IL4I1+ Macrophages and TDO2+ myofibroblasts drive AhR-mediated immunosuppression and ferroptosis resistance in solid predominant lung adenocarcinoma. Adv. Sci. (Weinh) 13:e13606. DOI:10.1002/advs.202513606 |
| [150] | Vitale I., Manic G., Coussens L.M., et al. (2019). Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30:36−50. DOI:10.1016/j.cmet.2019.06.001 |
| [151] | DeNardo D.G. and Ruffell B. (2019). Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19:369−382. DOI:10.1038/s41577-019-0127-6 |
| [152] | Liu Y., Dai Y. and Wang L. (2026). Spatial omics at the forefront: Emerging technologies, analytical innovations, and clinical applications. Cancer Cell 44:24−49. DOI:10.1016/j.ccell.2025.12.009 |
| [153] | He Y., Zhang W., Guo Z., et al. (2026). Superparamagnetic iron oxide nanoparticle restores gut microbiota homeostasis to enhance lung cancer immunotherapy. Natl. Sci. Rev. 13:nwaf565. DOI:10.1093/nsr/nwaf565 |
| [154] | Liu X., Fang S., Ren X., et al. (2025). GBP2 condensates promote ferroptosis to sensitize anti-PD-L1 immunotherapy in melanoma. Nat. Commun. 17:964. DOI:10.1038/s41467-025-67690-9 |
| [155] | Lyu Q., Liu C., Li S., et al. (2025). Pre-activation of T cell immunity potentiates ferroptotic cell death through arachidonic acid hybridized nanovesicles. J. Nanobiotechnology 23:718. DOI:10.1186/s12951-025-03797-x |
| [156] | Tang C., He C., Wang D., et al. (2025). Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma. Nat. Commun. 16:10096. DOI:10.1038/s41467-025-65056-9 |
| [157] | Su G.L., Zhang M.J., Li H., et al. (2025). Dissecting tertiary lymphoid structures in cancer: Maturation, localization and density. Theranostics 15:9459−9485. DOI:10.7150/thno.113940 |
| [158] | Wu X., Huang Q., Chen X., et al. (2025). B cells and tertiary lymphoid structures in tumors: Immunity cycle, clinical impact, and therapeutic applications. Theranostics 15:605−631. DOI:10.7150/thno.105423 |
| [159] | Zhu G., Nemoto S., Mailloux A.W., et al. (2018). Induction of tertiary lymphoid structures with antitumor function by a lymph node-derived stromal cell line. Front. Immunol. 9:1609. DOI:10.3389/fimmu.2018.01609 |
| [160] | Argyris D.G., Johnson L., Hägglöf T., et al. (2026). Emerging involvement of CXCL13 in cancer development and progression. Cytokine Growth Factor Rev. 87:73−88. DOI:10.1016/j.cytogfr.2025.12.005 |
| [161] | Rodriguez A.B., Peske J.D., Woods A.N., et al. (2021). Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36:109422. DOI:10.1016/j.celrep.2021.109422 |
| [162] | Lei L., Long J., Chen C., et al. (2026). Tumor vasculature-mediated formation of tertiary lymphoid structures: Unraveling spatiotemporal coupling to optimize vasculo-immunotherapy. Biochem. Pharmacol. 244:117574. DOI:10.1016/j.bcp.2025.117574 |
| [163] | Zhang M.J., Wen Y. and Sun Z.J. (2025). The impact of metabolic reprogramming on tertiary lymphoid structure formation: Enhancing cancer immunotherapy. BMC Med. 23:217. DOI:10.1186/s12916-025-04037-7 |
| [164] | Xu C., Sun S., Johnson T., et al. (2021). The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 35:109235. DOI:10.1016/j.celrep.2021.109235 |
| [165] | Pacella I., Pinzon Grimaldos A., Rossi A., et al. (2024). Iron capture through CD71 drives perinatal and tumor-associated Treg expansion. JCI Insight 9. DOI:10.1172/jci.insight.167967 |
| [166] | Marine J.C., Dawson S.J. and Dawson M.A. (2020). Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20:743−756. DOI:10.1038/s41568-020-00302-4 |
| [167] | Sharma P., Hu-Lieskovan S., Wargo J.A., et al. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707−723. DOI:10.1016/j.cell.2017.01.017 |
| [168] | Boumahdi S. and de Sauvage F.J. (2020). The great escape: Tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19:39−56. DOI:10.1038/s41573-019-0044-1 |
| [169] | Zhu J.F., Guo D.P., Lv H.N., et al. (2025). Histone lactylation-mediated up-regulation of IGF2BP2 enhances ferroptosis resistance via Nrf2 in colorectal cancer. Clin. Transl. Med. 15:e70551. DOI:10.1002/ctm2.70551 |
| [170] | Zaretsky J.M., Garcia-Diaz A., Shin D.S., et al. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375:819−829. DOI:10.1056/NEJMoa1604958 |
| [171] | Clogston J.D., Foss W., Harris D., et al. (2024). Current state of nanomedicine drug products: An industry perspective. J. Pharm. Sci. 113:3395−3405. DOI:10.1016/j.xphs.2024.09.005 |
| [172] | Dadfar S.M., Roemhild K., Drude N.I., et al. (2019). Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv. Drug Deliv. Rev. 138:302−325. DOI:10.1016/j.addr.2019.01.005 |
| [173] | Tian J., Song X., Wang Y., et al. (2022). Regulatory perspectives of combination products. Bioact. Mater. 10:492−503. DOI:10.1016/j.bioactmat.2021.09.002 |
| [174] | Singh N., Jenkins G.J., Asadi R., et al. (2010). Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 1. DOI:10.3402/nano.v1i0.5358 |
| [175] | Arami H., Khandhar A., Liggitt D., et al. (2015). In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem. Soc. Rev. 44:8576−8607. DOI:10.1039/c5cs00541h |
| [176] | Mazuel F., Espinosa A., Luciani N., et al. (2016). Massive intracellular biodegradation of iron oxide nanoparticles evidenced magnetically at single-endosome and tissue levels. ACS Nano 10:7627−7638. DOI:10.1021/acsnano.6b02876 |
| [177] | Lartigue L., Alloyeau D., Kolosnjaj-Tabi J., et al. (2013). Biodegradation of iron oxide nanocubes: High-resolution in situ monitoring. ACS Nano 7:3939−3952. DOI:10.1021/nn305719y |
| [178] | Xie W., Guo Z., Gao F., et al. (2018). Shape-, size- and structure-controlled synthesis and biocompatibility of iron oxide nanoparticles for magnetic theranostics. Theranostics 8:3284−3307. DOI:10.7150/thno.25220 |
| [179] | Auerbach M., Chertow G.M. and Rosner M. (2018). Ferumoxytol for the treatment of iron deficiency anemia. Expert Rev. Hematol. 11:829−834. DOI:10.1080/17474086.2018.1518712 |
| [180] | Yang C., Li S. and Wang L. (2025). Engineered iron oxide nanoplatforms: Reprogramming immunosuppressive niches for precision cancer theranostics. Mol. Cancer 24:225. DOI:10.1186/s12943-025-02443-2 |
| [181] | Moloney C., Roy Chaudhuri T., Spernyak J.A., et al. (2023). Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition. Acta Biomater. 158:611−624. DOI:10.1016/j.actbio.2022.12.057 |
| Chen S., Wang H., Gan Y., et al. (2026). Iron-based materials for sequential tumor microenvironment reprogramming: From mechanical decompression to immune remodeling. The Innovation Oncology 1:100044. https://doi.org/10.59717/j.xinn-oncol.2026.100044 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Conceptual framework of SMR (T0-T2) by iron-based nanomaterials
T0-T1 SMR mediated by iron-based nanomaterials
Beneficial and detrimental outcomes of ferroptosis during SMR